CONDENSED CONSOLIDATED STATEMENTS of SHAREHOLDERS' DEFICIT (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Noncontrolling Interest	Accumulatd Deficit [Member]	Total Deficit Member
Balance, shares at Dec. 31, 2023		76,247,370
Balance, amount at Dec. 31, 2023	$ (45,005,297)	$ 7,627	$ 181,753,261	$ (1,473,852)	$ (225,292,335)	$ (43,531,447)
Exercise of cashless warrants, shares		871,620
Exercise of cashless warrants, amount	0	$ 87	(87)	0	0	0
Exercise of common stock options, shares		148,000
Exercise of common stock options, amount	156,897	$ 15	156,882	0	0	156,897
Issuance of common shares for consulting services, shares		30,000
Issuance of common shares for consulting services, amount	43,800	$ 3	43,797	0	0	43,800
Dividend-in-kind of Novustera, Inc. common stock to shareholders	(1,361,788)	0	0	0	(1,361,788)	(1,361,788)
Stock compensation - options	986,132	0	986,132	0	0	986,132
Net loss, as restated	(7,021,123)	$ 0	0	(79,760)	(6,941,363)	(6,941,363)
Balance, shares at Mar. 31, 2024		77,296,990
Balance, amount at Mar. 31, 2024	(52,201,381)	$ 7,732	182,939,985	(1,553,612)	(233,595,486)	(50,647,769)
Balance, shares at Dec. 31, 2024		77,996,079
Balance, amount at Dec. 31, 2024	(81,051,810)	$ 7,802	186,407,169	(1,561,666)	(265,905,115)	(79,490,144)
Stock compensation - options	518,624	0	518,624	0	0	518,624
Net loss, as restated	(6,656,039)	$ 0	0	(3,276)	(6,652,763)	(6,652,763)
Common stock issued to settle accounts payable and accrued expenses, shares		2,495,770
Common stock issued to settle accounts payable and accrued expenses, amount	1,544,103	$ 244	1,543,859	0	0	1,544,103
Balance, shares at Mar. 31, 2025		80,491,849
Balance, amount at Mar. 31, 2025	$ (85,645,122)	$ 8,046	$ 188,469,652	$ (1,564,942)	$ (272,557,878)	$ (84,080,180)